We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Albemarle Better Positioned After Its Deleveraging Actions?
Read MoreHide Full Article
Key Takeaways
Albemarle paid down $1.3B of debt, cutting annual interest expense by about $60M.
Albemarle reduced long-term debt to $1.81B and ended Q1 with 1x net debt-to-EBITDA.
ALB has roughly $2.7B in liquidity, with no major debt maturities due until late 2028.
Albemarle Corporation (ALB - Free Report) remains committed to paying down debt and strengthening its balance sheet. The company paid down $1.3 billion of outstanding debt in March 2026, reducing annual interest expense by roughly $60 million. This followed the successful divestments of the controlling stake in Ketjen and its 50% interest in the Eurecat joint venture, which together generated $670 million in pre-tax proceeds.
ALB’s long-term debt was $1.81 billion at the quarter-end, down from $3.12 billion at the end of 2025. The company ended the first quarter with a net debt-to-EBITDA leverage ratio of 1x. It has no major maturities due until late 2028.
At the end of the quarter, ALB had liquidity of around $2.7 billion, including cash and cash equivalents of around $1.1 billion. Its deleveraging efforts are expected to continue to result in improved balance sheet and financial flexibility while reducing interest expenses.
Among its peers, Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) exited the first quarter with long-term debt of around $4.79 billion, up from $4.22 billion as of Dec. 31, 2025. SQM had strong liquidity, with cash and cash equivalents of around $2.8 billion at the end of the quarter. Sociedad Quimica, in early December 2025, issued a hybrid bond for roughly $430 million to refinance debt and fund its investment plan.
ICL Group Ltd. (ICL - Free Report) ended the first quarter with outstanding net debt of roughly $2.57 billion, up $309 million from the end of 2025. Including unutilized revolving credit facility and securitization, ICL Group had cash resources of $1.49 billion at the end of the quarter. ICL has priced a private offering of $800 million senior notes due 2036 and plans to use part of the net proceeds from the offering for the repayment, in part or in full, of outstanding borrowings under its revolving credit facility maturing in April 2030, and to repay other debt.
ALB’s Price Performance, Valuation & Estimates
Albemarle has gained 25.4% in the past six months compared with the Zacks Chemical - Diversified industry’s rise of 25.9%.
Image Source: Zacks Investment Research
ALB is currently trading at a forward price-to-sales ratio of 3.24, above the industry. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ALB’s 2026 earnings implies a year-over-year rise of 1,668.4%. The EPS estimates for 2026 have been trending higher over the past 60 days.
Image Source: Zacks Investment Research
ALB stock currently carries a Zacks Rank #1 (Strong Buy).
View the Zacks #1 Rank List
Image: Bigstock
Is Albemarle Better Positioned After Its Deleveraging Actions?
Key Takeaways
Albemarle Corporation (ALB - Free Report) remains committed to paying down debt and strengthening its balance sheet. The company paid down $1.3 billion of outstanding debt in March 2026, reducing annual interest expense by roughly $60 million. This followed the successful divestments of the controlling stake in Ketjen and its 50% interest in the Eurecat joint venture, which together generated $670 million in pre-tax proceeds.
ALB’s long-term debt was $1.81 billion at the quarter-end, down from $3.12 billion at the end of 2025. The company ended the first quarter with a net debt-to-EBITDA leverage ratio of 1x. It has no major maturities due until late 2028.
At the end of the quarter, ALB had liquidity of around $2.7 billion, including cash and cash equivalents of around $1.1 billion. Its deleveraging efforts are expected to continue to result in improved balance sheet and financial flexibility while reducing interest expenses.
Among its peers, Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) exited the first quarter with long-term debt of around $4.79 billion, up from $4.22 billion as of Dec. 31, 2025. SQM had strong liquidity, with cash and cash equivalents of around $2.8 billion at the end of the quarter. Sociedad Quimica, in early December 2025, issued a hybrid bond for roughly $430 million to refinance debt and fund its investment plan.
ICL Group Ltd. (ICL - Free Report) ended the first quarter with outstanding net debt of roughly $2.57 billion, up $309 million from the end of 2025. Including unutilized revolving credit facility and securitization, ICL Group had cash resources of $1.49 billion at the end of the quarter. ICL has priced a private offering of $800 million senior notes due 2036 and plans to use part of the net proceeds from the offering for the repayment, in part or in full, of outstanding borrowings under its revolving credit facility maturing in April 2030, and to repay other debt.
ALB’s Price Performance, Valuation & Estimates
Albemarle has gained 25.4% in the past six months compared with the Zacks Chemical - Diversified industry’s rise of 25.9%.
ALB is currently trading at a forward price-to-sales ratio of 3.24, above the industry. It carries a Value Score of D.
The Zacks Consensus Estimate for ALB’s 2026 earnings implies a year-over-year rise of 1,668.4%. The EPS estimates for 2026 have been trending higher over the past 60 days.
ALB stock currently carries a Zacks Rank #1 (Strong Buy).
You can see the complete list of today’s Zacks #1 Rank stocks here.